New Insights of Anti-Hyperglycemic Agents and Traditional Chinese Medicine on Gut Microbiota in Type 2 Diabetes
Yanxia Chen,Mian Wang
DOI: https://doi.org/10.2147/DDDT.S334325
2021-11-30
Abstract:Yanxia Chen, Mian Wang Department of Endocrinology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050051, People's Republic of China Correspondence: Mian Wang Department of Endocrinology, The Second Hospital of Hebei Medical University, 215 Hepingxi Road, Shijiazhuang, Hebei, 050051, People's Republic of China Email Type 2 diabetes mellitus (T2DM) is a widespread metabolic disease characterized by chronic hyperglycemia. Human microbiota, which is regarded as a "hidden organ", plays an important role in the initiation and development of T2DM. In addition, anti-hyperglycemic agents and traditional Chinese medicine may affect the composition of gut microbiota and consequently improve glucose metabolism. However, the relationship between gut microbiota, T2DM and anti-hyperglycemic agents or traditional Chinese medicine is poorly understood. In this review, we summarized pre-clinical and clinical studies to elucidate the possible underlying mechanism. Some anti-hyperglycemic agents and traditional Chinese medicine may partly exert hypoglycemic effects by altering the gut microbiota composition in ways that reduce metabolic endotoxemia, maintain the integrity of intestinal mucosal barrier, promote the production of short-chain fatty acids (SCFAs), decrease trimethylamine-N-oxide (TMAO) and regulate bile acid metabolism. In conclusion, gut microbiota may provide some new therapeutic targets for treatment of patients with diabetes mellitus. Keywords: gut microbiota, anti-hyperglycemic agents, traditional Chinese medicine, type 2 diabetes mellitus Diabetes mellitus (DM), which is contributed to genetic and/or environmental factors, is the most prevalent metabolic disease worldwide characterized by chronic hyperglycemia. Type 2 diabetes mellitus (T2DM), which results from insulin resistance and/or impaired insulin secretion, accounts for more than 90% of patients with DM. Long-term hyperglycemia can result in detrimental micro- and macrovascular complications, involving many organs and systems, especially kidneys, nervous system, eyes and blood vessel. 1 Tens of trillions of microorganisms indigenously colonize the gastrointestinal tract immediately after birth, collectively termed as gut microbiota. Gut microbiota is a highly complex and dynamic microbial ecosystem and may be regarded as a "hidden organ". Human microbiota, which is considered as a metabolic organ, can perform diverse physiological functions to maintain homeostasis in health. 2 It is estimated that the number of microbial genes approximately exceeds 100-fold higher than that of human genome. The gut microbiota, also considered as the "second genome" of the host, provides humans with additional biological and metabolic functions that cannot be performed by the host. 3 The composition of the gut microbiota is influenced by several variables including diet, sex, age, lifestyle, environment, geographical location and genetic background. 4 The gut microbiota is dominated by four phyla: Firmicutes (Gram-positive, 60–65%), Bacteroidetes (Gram-negative, 20–25%), Proteobacteria (Gram-negative, 5–10%), Actinobacteria (Gram-positive, 3%). 5 Growing evidences suggest that the perturbation of normal intestinal microbiota composition, also termed as dysbiosis, may break the homeostasis and result in a variety of common metabolic diseases, including diabetes and diabetic complications. 6,7 Over the last few decades, a myriad of original research indicates that there is an association between gut microbiota and T2DM. In previous years, some reviews published have reported the interaction between anti-hyperglycemic agents and gut microbiota. 8,9 The association between human microbiome and traditional Chinese medicine on healthcare and cancer treatment has gained attention in recent years, 10,11 but reviews on the association between antidiabetic effect of the traditional Chinese medicine and gut microbiota are insufficient. Accordingly, we summarized the latest literatures and explored the potential mechanisms of how anti-hyperglycemic agents and traditional Chinese medicine influenced the gut microbiota, which might provide some new therapeutic targets of T2DM. Increasing clinical and animal researches have revealed the important role of gut microbiota dysbiosis in the initiation and development of T2DM. 7,12 Given that hyperglycemia also affect bacterial composition, 13,14 the gut microbiota and diabetes have a reciprocally regulatory relationship. 15 Several studies have determined that the gut microbiota dysbiosis leads to insulin resistance and T2DM through several mechanisms including lipopolysaccharide (LPS)-mediated metabolic endotoxemia (Figure 1A). LPS, which is a major component of the outer membrane of the -Abstract Truncated-